From June to July 2022, Professor Li Tang, co-founder of Leman Biotech, and his team were invited to attend two Gordon Research Conferences (GRCs) held in Rhode Island and Ventura, USA. These conferences were among the top events in the field. During these conferences, Professor Li Tang presented the latest metabolic engineering CAR-T technology developed by Leman Biotech to an international audience of scientists. The technology has achieved a success rate of over 80% in various mouse solid tumor models. The presentations received positive feedback from attendees. Professor Li Tang also engaged in discussions with prominent immunologists and immunoengineering experts such as Prof. Hongbo Chi, Prof. Darrell Irvine, Prof. David Mooney, Prof. Wilson Wong, Prof. Ming Li, Prof. Yvonne Chen, Prof. Suzie Pun, and Dr. Edmund K. Waller.
Leman Biotech is a clinical-staged cancer immunotherapy company co-founded by Professor Li Tang of the Swiss Federal Institute of Technology in Lausanne (EPFL) and AI-driven drug R&D leader XtalPi. The company combines innovative metabolic reprogramming technology with cutting-edge AI drug discovery platform to develop next-generation cancer immunotherapies. The core technology Meta 10 has the potential to cure solid tumors, as demonstrated in the published research in the top academic journal Nature Immunology, and has PCT patents in 56 countries and regions, covering major economies in the world. The company has a highly qualified R&D team, with over 70% of its personnel having graduated from esteemed Chinese and international universities and holding extensive industrial experience. Several of Leman Biotech's R&D pipelines are in advanced stage of development, including a metabolically armed CAR-T cell therapy in IIT clinical research stage. In December 2021, just half a year after its inception, Leman Biotech completed a successful angel round of financing, raising nearly $11 million, with plans for further financing underway. Leman Biotech is committed to finding solutions to the bottlenecks in cancer immunotherapy, improving the response rate and efficacy, and making unremitting efforts to achieve the ultimate goal of curing cancer.
The Gordon Research Conference (GRC), established in 1931, is a non-profit organization that brings together scientists from around the world to discuss the latest research in various fields and provides a platform for the presentation and discussion of cutting-edge research in the biological, chemical, physical, and engineering sciences and their related disciplines. The GRC has strict requirements for both presenters and attendees, and only invites well-renowned scientists with significant impact in their fields. The 2022 Immunoengineering Branch of GRC aimed to facilitate meaningful interactions among immunologists, bioengineers, chemists, mathematicians, physicists, systems biologists, and clinicians, and promote collaboration and translational applications of basic immunoscience, such as cancer immunotherapy. The GRC is recognized as a world-class academic conference and is highly respected in the scientific community. Leman Biotech's participation in the conference not only built strong academic connections with global scientists, but also boosted the international reputation and influence of their core technology, Meta 10.
